Drug
Andecaliximab clinical trials
Also written GS-5745.
- studies test it
- 12
- open now
- 1
- in phase 3
- 3
- first study started
- 2013
Keep track of what changes. Save the andecaliximab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
12 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 3 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 7
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Gilead Sciences (10) · Ashibio Inc (2)
Studies
Open first, then newest update. How each study uses andecaliximab is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.RecruitingPhase 1/2Ashibio IncNCT07024407Written as Andecaliximab
- A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)Active, not recruitingPhase 2/3Ashibio IncNCT06508021Written as Andecaliximab
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative ColitisCompletedPhase 1Gilead SciencesNCT01831427Written as Andecaliximab
- Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction AdenocarcinomaCompletedPhase 2Gilead SciencesNCT02864381Written as Andecaliximab
- Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 1Gilead SciencesNCT02077465Written as Andecaliximab
- Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaCompletedPhase 3Gilead SciencesNCT02545504Written as Andecaliximab
- Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's DiseaseTerminatedPhase 2Gilead SciencesNCT02405442Written as Andecaliximab
- Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative ColitisTerminatedPhase 2/3Gilead SciencesNCT02520284Written as Andecaliximab
- Effect of Andecaliximab on FEV1 in Adults With Cystic FibrosisTerminatedPhase 2Gilead SciencesNCT02759562Written as Andecaliximab
- Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid ArthritisTerminatedPhase 2Gilead SciencesNCT02862574Written as Andecaliximab
- Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid ArthritisCompletedPhase 1Gilead SciencesNCT02176876Written as GS-5745
- Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy AdultsCompletedPhase 1Gilead SciencesNCT02209987Written as GS-5745 SC
Given in every arm · 2 — andecaliximab is usual care beside what is tested
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction AdenocarcinomaTerminatedPhase 1Gilead SciencesNCT02862535Written as Andecaliximab
- Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid TumorsCompletedPhase 1Gilead SciencesNCT01803282Written as Andecaliximab
Codes
What other systems call andecaliximab · ClinicalTrials.gg INT000763
- MeSH (NLM) C000621903andecaliximabOne source NLM
- UNII (FDA) 571045EIM4ANDECALIXIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q48975957andecaliximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C105803AndecaliximabOne source FDA
- DrugBank DB12296One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621903 | andecaliximab | One source NLM |
| UNII (FDA) | 571045EIM4 | ANDECALIXIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q48975957 | andecaliximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C105803 | Andecaliximab | One source FDA |
| DrugBank | DB12296 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.